Mace L. Rothenberg, MD, is Chief Medical Officer & Senior Vice President, Clinical Development & Medical Affairs for the Oncology Business Unit at Pfizer's Global Research and Development site in La Jolla, Calif. He joined Pfizer in 2008 and is responsible for overseeing worldwide clinical research and development as well as post-marketing evaluation and monitoring for all oncology products. Mace is also involved in the evaluation of potential in-license of oncology products from outside sources. At Pfizer, Mace is a member of the Leadership Team in the Oncology Business Unit and a member of the Senior Management Team in Pfizer, Inc.
Prior to joining Pfizer, Mace was Professor of Medicine at the Vanderbilt University Medical Center and Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center. He was active in clinical-translational research in oncology for more than 20 years. Mace was the recipient of several research grants from the National Cancer Institute and served on several NIH study sections.
Mace has published more than 150 articles and books, primarily in the areas of early stage drug development, gastrointestinal malignancies and ovarian cancer. Mace has served on the editorial boards of several leading medical journals, including the Journal of Clinical Oncology and Clinical Cancer Research. His work was critical to the development and eventual FDA approval of irinotecan (CPT-11, Camptosar®) in 1996 and oxaliplatin (Eloxatin®) in 2002 for colorectal cancer and gemcitabine (Gemzar®) in 1996 for pancreatic cancer. In addition to his clinical research accomplishments, Mace has been recognized for his compassionate care of cancer patients. In 2008, he received the Lane W. Adams Quality of Life Award from the American Cancer Society, honoring him as one of the nation's top cancer caregivers.
Mace received his B.A. from the University of Pennsylvania in 1978 and his M.D. from the New York University School of Medicine in 1982. He trained as an Intern and Resident in Internal Medicine at Vanderbilt University and obtained his medical oncology training at the National Cancer Institute.